Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?The Motley Fool • 08/27/21
CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primatesMarket Watch • 08/16/21
CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine StudyZacks Investment Research • 07/01/21
CureVac Stock Drops After Final Results Confirm Its COVID-19 Vaccine Trails RivalsBenzinga • 07/01/21
The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key studyMarket Watch • 07/01/21
Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?The Motley Fool • 06/29/21
How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's ChallengesThe Motley Fool • 06/23/21